dm+d
37733411000001108
New Medicines
TalzennaMetastatic castration-resistant prostate cancer - first-line with enzalutamide
Information
Talzenna
Licence extension / variation
Pfizer
Pfizer
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Category
Poly(ADP-ribose) polymerase (PARP) inhibitor
Prostate cancer is the most common cancer in men and makes up 26% of all male cancer diagnoses in the UK. The age-standardised incidence of prostate cancer in the UK in 2014 was 175 per 100,000 population [1]
Metastatic castration-resistant prostate cancer - first-line with enzalutamide
Oral
Further information
Yes
Evidence based evaluations
TalzennaDDR-deficient metastatic castration-sensitive prostate cancer - first-line with enzalutamide
Information
Talzenna
Licence extension / variation
Pfizer
Pfizer
Development and Regulatory status
None
None
Phase III Clinical Trials
Category
Poly(ADP-ribose) polymerase (PARP) inhibitor, taken once daily
Prostate cancer is the most common cancer in men and makes up 26% of all male cancer diagnoses in the UK. The age-standardised incidence of prostate cancer in 2014 was 175 per 100,000 population [1]. Germline deleterious mutations in DDR genes are present in 8–16% of metastatic prostate cancer patients. There is strong emerging evidence that some germline and somatic DDR defects may predict the response to poly-ADP ribose polymerase (PARP) inhibitors and platinum-based chemotherapy [2].
DDR-deficient metastatic castration-sensitive prostate cancer - first-line with enzalutamide
Oral